Co-Diagnostics (CODX) Reports FY21 $97.9M, EPS of $1.23

Co-Diagnostics (NASDAQ: CODX) reported Q4 EPS of $, $0.12 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $0 versus the consensus estimate of $20.93 million.

GUIDANCE:

Co-Diagnostics sees Q1 2022 EPS of $0.17-$0.20. Co-Diagnostics sees Q1 2022 revenue of $21-22 million.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Is the global equity rally broadening? UBS weighs in
• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance